Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs Stryker Corporation — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $75.66, while Stryker Corporation trades at $319.04 (market cap $122.35B). The key difference: Stryker Corporation pays a 1% dividend while Invesco S&P 500 Low Volatility ETF pays none, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| SPLV | SYK | |
|---|---|---|
52-Week High | $77.45 | $403.53 |
52-Week Low | $70.30 | $282.58 |
Market Cap | — | $122.35B |
Sector | — | Technology |
Enterprise Value | — | $134.10B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV trades at $76.09, down 0.63% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market tensions. Recent news highlights its appeal as a defensive play during geopolitical and inflation concerns. Dividend payments of $0.14 per share are scheduled for mid-2026.
The outlook for SPLV is positive as a defensive equity holding, with low volatility strategies gaining traction in uncertain markets. Key risks include reliance on market volatility for relevance and potential underperformance in strong bull markets. Analyst sentiment is neutral to positive given current macroeconomic conditions.
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
